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ABSTRACT
The identification of genes with specific patterns of
change (e.g. down-regulated and methylated) as phe-
notype drivers or samples with similar profiles for
a given gene set as drivers of clinical outcome, re-
quires the integration of several genomic data types
for which an ‘integrate by intersection’ (IBI) approach
is often applied. In this approach, results from sep-
arate analyses of each data type are intersected,
which has the limitation of a smaller intersection with
more data types. We introduce a new method, GISPA
(Gene Integrated Set Profile Analysis) for integrated
genomic analysis and its variation, SISPA (Sample
Integrated Set Profile Analysis) for defining respec-
tive genes and samples with the context of similar, a
priori specified molecular profiles. With GISPA, the
user defines a molecular profile that is compared
among several classes and obtains ranked gene sets
that satisfy the profile as drivers of each class. With
SISPA, the user defines a gene set that satisfies a
profile and obtains sample groups of profile activity.
Our results from applying GISPA to human multiple
myeloma (MM) cell lines contained genes of known
profiles and importance, along with several novel
targets, and their further SISPA application to MM
coMMpass trial data showed clinical relevance.
INTRODUCTION
The widespread availability of cancer genomics data
prompts a critical, yet unanswered question: How do we
identify genetic drivers of a particular phenotype given the
diverse ways in which genes can be dysregulated? For a sin-
gle data type, such as gene expression (GE), well-established
methods exist, but introducing additional data types such as
CpG methylation, copy number (CN) and somatic gene mu-
tations make an integrated analysis much more challenging.
Assuming that genetic drivers can be identified from multi-
dimensional data, the subsequent question of how to iden-
tify ‘similar’ samples within another data set then arises.
When a single data type is present, methods of assessing
similarity exist (1,2), but finding ‘similar’ samples among
multidimensional data is a considerable challenge.
Integrate by intersection (IBI) is the simplest approach to
analyzing multidimensional data of several data types. With
IBI, the results of independent analyses from each data type
are intersected post hoc. While easily implemented, a ma-
jor limitation of this approach is that as the number of data
types increases, the intersection becomes small and smaller.
Various modeling approaches have also been used for inte-
grated analyses, which often require large sample sizes and
generally assume an analytical distribution describing the
relationship among data types (3). For example, in exam-
ining differential methylation associated GE changes, one
assumes that expression is modulated by differential methy-
lation.
Gene Integrated Set Profile Analysis (GISPA) is a novel
approach that combines and compares several genome-
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wide data types from three or more sample classes in order
to find the drivers of each class. GISPA produces ranked
gene sets within the context of an a priori specified molec-
ular profile, such as genes that have some combination of
increased CpG methylation, CN loss and decreased GE spe-
cific to a single sample or class. Sample Integrated Set Pro-
file Analysis (SISPA), a variation of GISPA, is a novel ap-
proach to find samples within the context of a similar, a pri-
ori multidimensional profile from a gene set of interest, ei-
ther GISPA-defined or by the user. GISPA and SISPA de-
rive results from a combined analysis of all data types; both
are non-parametric and therefore do not rely upon imposed
analytical distributions and crucially, do not require a large
sample size.
Here, we apply GISPA to RNA-Seq, DNA CpG methy-
lation and DNA CN data from three, extensively stud-
ied human multiple myeloma (MM) cell lines: KMS11 (4),
MM1s (5) and RPMI8226 (6). Having identified potential
driving genes’ profiles specific to each cell line, we apply
SISPA to identify patients with similar driving gene profiles
from a large MM clinical trial. Finally, we derive a differ-
ential prognostic, mutation dependency network based on
GISPA-defined sample-specific mutation profiles.
MATERIALS AND METHODS
Materials
Data generation. DNA and RNA were isolated from hu-
man myeloma cell lines and applied to array-based plat-
forms: Illumina Omni1 Quad and Illumina Infinium Hu-
man Methylation 450K following the manufacturers’ proto-
cols. For RNA-Seq, 3 g of total RNA was obtained using
the Illumina HiSeq at ∼1000X coverage. Prior to analysis,
proportions (e.g. CpG methylation beta values, variant pro-
portions) were transformed using log2((1 + p) / (1 − p)), and
GE data were transformed using log2(DESeq + 1). All mi-
croarray and RNA-Seq data analyses were done based on
(RefSeq) annotated, non-pseudo genes located on chromo-
somes 1 thru 22. Details on data processing are contained
in the Supplement.
Clinical associations. Data were obtained from the on-
going Multiple Myeloma Research Foundation (MMRF)
CoMMpass Trial (NCT0145429), a longitudinal study
in MM relating clinical outcomes to genomic and im-
munophenotypic profiles of CD138 selected plasma cells
from the bone marrow of newly diagnosed MM patients
(7). Data from 377 patients with available clinical outcomes,
Exome-Seq somatic mutations and CN segments and RNA-
Seq ensemble GE at pre-treatment were downloaded based
on the IA6 release of this trial from the MMRF researcher
gateway portal (https://research.themmrf.org). Data were
similarly transformed as with the HMCL’s. Sample z-scores
and gene set were obtained using the bioconductor R pack-
age, ‘GSVA’ (2) and a change point model applied to a
constructed composite score to define sample classes with
and without profile activity for a given gene set using our
SISPA method variation. Overall and progression-free sur-
vival analyses were done using SAS 9.3 (SAS Institute, Inc.,
Cary, NC, USA).
Network pathway analysis. The functional interaction (FI)
network analysis was done using the Reactome FI ap-
proach (8) and HyperModules software plugins (9), as im-
plemented in Cytoscape v3.2 (10).
miRNA associations. An in-house merger database (http:
//mirnamerger.org/) was used to search for known or pre-
dicted miRNA–mRNA target pairs against several public
databases for a gene set.
Methods
Herein, we adopt The Cancer Genome Atlas (TCGA)
nomenclature (https://tcga-data.nci.nih.gov/tcga/
dataAccessMatrix.htm) that references a specific data
type (RNA-Seq expression, DNA CpG methylation, etc.)
as a feature, with specific sub features such as a gene, probe
or CpG site collectively referred to as loci. A single-feature
profile is defined as a combination of locus-level changes
within a feature, while a combination of locus-level changes
summarized across features is used to define a multi-feature
profile.
Overview of GISPA. GISPA considers experiments with
genome-wide data on one or more features from samples
belonging to three or more classes. Given a user-defined
molecular profile, GISPA derives ranked gene lists that sat-
isfy this profile specific to each class. Below, we describe the
four fundamental steps of GISPA (Figure 1), with the de-
tails provided in Supplementary Methods.
Step 1: specifying a profile. A profile is defined by specify-
ing a priori, a change of either increase or decrease within
each of the features. For example, eight possible profiles ex-
ist for three features. An example of a three feature profile
relevant to cancer that we highlight in the results is that
of decreased GE with increased CpG methylation and de-
creased CN.
Step 2: calculating within-feature profile statistics (WFPS).
We introduce a novel statistic to filter genome-wide profile
changes as drivers for each class. Assume, for example, three
(single-sample) classes, C1, C2 and C3 in which we charac-
terize C1 relative to C2 and C3 on the basis of our specified
profile. We define gene sets that satisfy this profile as drivers
of C1 based on a filter statistic (see Supplementary Meth-
ods) with the following properties: (i) C1–C2 >> 0; (ii) C1–
C3 >> 0; and (iii) C2–C3 ≈ 0. Altogether, these properties
minimize the potential for ambiguities in defining gene sets.
Low WFPS values more closely correlate with the profile,
whereas high values correlate with an extreme opposite pro-
file. An empirical cumulative distribution function is con-
structed among the WFPS to define percentiles (see Supple-
mentary Methods, Eq. 3). Using the WFPS percentiles, we
define a between-genes, within-feature profile statistic (BG-
WFPS, see Supplementary Methods). The use of percentiles
enables a standardization of data such that the range be-
tween 0 and 1 is the same for each feature.
Step 3: calculating between-features profile statistic (BFPS).
We construct a between feature profile statistic by summing
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Figure 1. A Gene Integrated Set Profile Analysis (GISPA) overview illustrating the method. A three gene (G1, G2, G3) data set of two features, RNA-Seq
gene expression (GE; feature 1) and CpG methylation of two sites (feature 2) as an example from three cell lines (C1, C2, C3). C1 is the cell line of interest
to be compared against C2 and C3 based on the specified profile of increased GE and decreased CpG methylation (step 1). Using normalized data, shown
as grids for each feature with ‘high’ (in red) and ‘low’ (in blue) values, a profile statistic is defined for each gene, within each feature among the cell lines
that is based on the differences between C1 with C2 and C3, and between C2 and C3. This statistic is then used to obtain percentiles (step 2) that are
summed between features for all probe and CpG site combinations to define a between feature profile statistic (step 3). Based on the summed percentiles,
a prominent feature driving the between-feature profile statistic for each gene is defined as the feature with the maximum percentage contribution to the
summed percentiles (step 4). This percent contribution assigns smaller values with a higher percentage than large values, since small values of the summed
percentiles imply greater profile support. A multiple change point model (cpm) is applied to the (–log10 transformed) summed percentiles to select genes
with extreme values (change point 1) followed by the next most extreme (change point 2), etc. and denote these gene sets as ranked levels of support for
the specified profile (step 4). Using these ranked gene sets and patient data, a sample profile score is defined based on a within-gene z-score among samples
that is summed among genes within each feature, and in this example, subtracted between features, and applied in a second cpm to define sample classes
with and without profile activity (see Supplementary Methods).
the WFPS percentiles for each gene. For some data types,
such as CpG methylation, the number of CpG sites varies
greatly among genes and therefore genes with a large num-
ber of CpG sites are more likely to be selected as part of a
gene set. To address this issue, we generate a BFPS statis-
tic for each gene and CpG site combination, and select the
CpG site with the smallest summed percentile to be carried
forward in step 3. In the case of transcript level GE data, we
construct a combined data set based on compatible feature
combinations such that if a CpG site does not correspond
to a transcript, their combination is filtered. We obtain each
feature’s percentage of the summed percentiles and use this
to define the feature associated with the highest percentage
as the prominent feature. Since low values of the WFPS cor-
relate with the profile of interest, we define an inverse pro-
portion such that lower values reflect a higher percentage
contribution to the total than high values (see Supplemen-
tary Methods).
Step 4: deriving gene lists. We derive ranked gene sets ac-
cording to various levels of support for the molecular pro-
file of interest by applying a change point model (cpm) to
the transformed (-log10) summed percentiles (BFPS). The
use of a cpm in this context is analogous to applying a
segmentation algorithm to array CN data, in which seg-
ments are typically defined by a breakpoint so that neigh-
boring regions have different mean intensities. With our
method, gene sets are formed by change points that are de-
fined by successive differences in variances in the distribu-
tion of transformed percentiles. Because of the interpreta-
tion of our profile statistic, these gene sets are ranked ac-
cording to those that most satisfy the profile (change point
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1), next most (change point 2), etc. Additionally, one is able
to estimate the statistical significance of genes sets in charac-
terizing a class by ‘gene randomization’ (see Supplementary
Methods).
SISPA. SISPA defines samples with and without profile
activity, on average, among genes defined by a set, by apply-
ing a cpm to a composite, between features z-score formed
by adding or subtracting individual sample scores between
features, depending on the profile, between features (see Fig-
ure 1 and Supplementary Methods).
The R code to run GISPA is available for down-
load at https://github.com/BhaktiDwivedi. The Biocon-
ductor R package for SISPA is available at https://www.
bioconductor.org/packages/release/bioc/html/SISPA.html.
RESULTS
All gene set results for two- and three-feature profiles are
displayed in Supplementary Tables S1–S4.
Single-feature GISPA
As a proof of principle, we applied GISPA to single fea-
tures, firstly SNP array CN and then RNA-Seq GE from
the KMS11, MM1s and RPMI8226 MM cell lines (see
Methods, Appendices 2 and 3). GISPA identified a deleted
gene set specific to KMS11 that contained TP53 (Supple-
mentary Figure S1), and a set specific to MM1s contain-
ing CDKN2A (data not shown); these gene deletions are
known abnormalities in the three cell lines (4,5). GISPA ad-
ditionally identified FGFR3 with increased GE specific to
KMS11. This cell line has a t(4;14) translocation that re-
sults in FGFR3 over expression. Interestingly, FGFR3 fell
between the first (cpt1) and second change points (cpt2).
For RNA-Seq GE data in particular, there is often a mix-
ture of ‘non-zero’ and ‘zero’ GE data such that genes with
non-zero GE in the class of interest and zero GE in the com-
parison classes are first selected in cpt1 and genes with non-
zero GE in all classes in cpt2. In such cases, the extension to
more than one cpt may be needed to accommodate such a
mixture, as in the case of FGFR3, a gene with non-zero GE
in all three classes that is specifically up-regulated KMS11.
Thus, if using a single feature profile of increased GE, one
may consider using gene sets from three change points.
Two-feature GISPA
We next generated two-feature profiles incorporating de-
creased RNA-Seq GE with decreased CN. Among the
KMS11 selected genes (Figure 2; Supplementary Figure
S2 for MM1s and RPMI cell lines), TP53 was, again, the
topmost, showing CN change as the prominent feature.
Among the other selected genes, MAML2 had not pre-
viously been associated with MM and was also found as
part of a novel gene fusion (11). Additionally, we applied
GISPA to identify RNA-Seq derived coding variants with
increased GE (Supplementary Figure S3), and coding vari-
ants with increased CpG methylation (Supplementary Fig-
ure S4) by implementing a ‘carry one forward’ approach
(see Supplementary Methods) due to the varying number of
variants and CpG sites per gene. Variant status was used as
a continuous variable based around the mutant allele frac-
tion predicted from RNA-Seq so that even low-level mo-
saic mutations are considered in the analysis. GISPA iden-
tified known and novel expressed variants specific to each
cell line. Among the GISPA defined genes supporting the
profile of variants with increased GE in the KMS11 cell
line as compared to both MM1s and RPMI8226 cell lines
(a.k.a. ‘KMS11 selected expressed variants’), FGFR3 was
the top gene showing, as expected, a previously reported
missense Y373C mutation (COSMIC ID, COSM718) with
highly skewed GE toward the mutated copy (all RNA-Seq
reads contained the variant allele; Supplementary Table S2)
(12).
Three-feature GISPA
We next used GISPA to identify genes that satisfied the
three-feature, cancer relevant profile of having loci with de-
creased GE and CN with increased CpG methylation as cell
line-specific drivers. KMS11 selected genes with this profile
are shown in Figure 3 (Supplementary Figure S5 for MM1s
and RPMI cell lines).
We compared GISPA to the intersecting approach for
defining KMS11 selected genes with our three-feature pro-
file. We identified genes with increased CpG methylation in
KMS11 versus MM1s and RPMI cell lines using a one-
sided t-test and derived a list of differentially expressed
genes using the DESeq package (13). By applying a P-value
threshold of 0.01 for both methylation and GE results, a GE
fold-change of at least 2, and requiring a CN loss specific to
KMS11, no genes were identified as intersecting among the
data type results. After removing the 2-fold GE fold-change
criterion and applying the same P-value threshold, 40 genes
were identified, of which MERTK, was in common with the
GISPA gene set. These 40 genes were mostly associated with
variable methylation changes which the GISPA profile pe-
nalizes by the additional requirement of little to no methy-
lation differences between comparative cell lines.
MERTK was among the top KMS11 selected genes with
a profile of decreased GE and decreased CN with increased
CpG methylation as compared to both MM1s and RPMI
cell lines with profiles of increased GE with decreased CpG
methylation and no CN change (Figure 3; Supplementary
Table S4). Additionally, a CN change is shown as the promi-
nent feature driving this profile in MERTK for KMS11
(Figure 3). MERTK is a suspected oncogene, over-expressed
in many different cancers and has been found to be mu-
tated in MM and melanoma leading to a potential onco-
genic function (14,15).
Among the other KMS11 selected genes with decreased
GE and increased CpG methylation with decreased focal
CN changes (CN segment less than 2% of the chromo-
some arm), VILL and TTC22 show GE as the prominent
feature, while EPS15 (Early Growth Factor Pathway Sub-
strate 15) show CpG methylation (Figure 3). EPS15 is in-
volved in translocations in acute leukemia (16), but as yet,
has not been linked to MM. Whole arm or interstitial dele-
tions of the chromosome 1p are observed in approximately
30% of myeloma patients and are associated with a poor
prognosis (17–19). Deletions of 1p12 and 1p32.3 are of par-
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Figure 2. Two feature GISPA identifies KMS11 selected genes with decreased gene expression (GE) and decreased copy number (CN). KMS11 selected,
change point 1 (cpt1) gene set results that satisfy the profile of decreased GE with decreased CN by CN segment as focal (F) or large = scale (LS) according
to whether the segment’s chromosome arm fraction was less than or greater than or equal to 2%, respectively (F1 = focal in cpt1l; LS1 = Large-Scale
in cpt1). Genes are sorted from the smallest to largest between-feature profile statistic. Left: Between-cell line differences. Within each data type: GE (in
orange) and CN change (in blue), a stacked bar denoting the percent contribution from each cell line to the summed total of each feature, GE and CN,
is displayed along a color gradient from darkest (KMS11) to medium (MM1s) to lightest (RPMI) shades. Among all genes selected, as expected, KMS11
percent contribution to total changes in each feature is the smallest for both GE and CN. Right: Between-feature Differences. The percent contribution from
each feature to the profile is displayed as a stacked bar. The genes, TP53, MAML2, TMEM102 and TMEM87B show CN change as the prominent feature
driving the profile, whereas APOBEC3A, FLRT3 and JAG1 show GE, and MERTK shows GE and CN as prominent features that equally contribute to
the profile. Depending upon the CN segment, MACROD2 is shown with CN or both CN and GE as prominent features.
Figure 3. Three Feature GISPA identifies KMS11 selected genes with decreased gene expression (GE), increased CpG methylation, and decreased copy
number (CN). KMS11 selected, change point 1 (cpt1) gene results that satisfy the profile of decreased GE with increased CpG methylation and decreased
(heterozygous) CN by CN segment as focal (F) or large = scale (LS) according to whether the segment’s chromosome arm fraction was less than or greater
than or equal to 2%, respectively (F1 = focal in cpt1l; LS1 = Large-Scale in cpt1). Genes are sorted from the smallest to largest between-feature profile
statistic. Left: Between-cell line differences. Within each data type: GE (in orange), CpG methylation (in purple) and CN change (in blue), a stacked bar
denoting the percent contribution from each cell line to the summed total of each feature, GE, CN and CpG methylation, is displayed along a color
gradient from darkest (KMS11) to medium (MM1s) to lightest (RPMI) shades. Among all genes selected, as expected, KMS11 percent contribution to
total changes in each feature is the smallest for GE, largest for CpG methylation and smallest for CN change. Right: Between-feature Differences. The
percent contribution from each feature to the profile is displayed as a stacked bar. The genes, EPS15 and ZNF187 show CpG methylation as prominent
features driving the profile, whereas TTC22, VILL, ZN501 and LRRC2 show GE, and MERTK, CN.
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ticular importance in MM as they contain tumor suppres-
sor genes, FAF1 and CDKN2C; both are in close proxim-
ity to TTC22 and EPS15. This raises the possibility that
these genes are co-deleted. However, the prominent CpG
methylation change of EPS15 implies that loss of function
of EPS15 may also have functional relevance for MM. We
confirmed EPS15 deletion by FISH and CpG methylation
by bisulfite sequencing as specific to the KMS11 cell line
(Supplementary Figure S6). Notably, EPS15 was not iden-
tified using an IBI approach, even with a more relaxed P-
value of 0.05 applied to the results. Among the MM1s and
RPMI selected gene set results (Supplementary Figure S5),
GISPA identified several known TSG’s linked to numerous
cancers, including CDKN2A, PARK2, ARID1B, PTPRD
and L3MBTL4, some of which have known associations
with MM (17,20–23).
Clinical and biological relevance
Clinical relevance. The large heterogeneity among vari-
ants precluded a direct clinical association analysis. In this
case, we demonstrate the use of GISPA to define sample-
specific gene sets specific to clinically distinct classes that
satisfy the two-feature profile of variants with increased
GE. We therefore investigated whether the two feature pro-
file of decreased GE and decreased CN cell line specific
GISPA gene set (Figure 2) had any clinical relevance. We
applied SISPA to Exome-Seq somatic mutations and CN,
and RNA-Seq GE from 377 newly diagnosed MM pa-
tients enrolled in the coMMpass trial (Appendix 3: Meth-
ods) (7) to define pre-treatment samples with similar pro-
files. SISPA identified 15 samples with decreased CN and
decreased GE profile based on the KMS11-specific cpt1
gene set (Figure 2). These fifteen patients had a significantly
(P = 0.011) shorter overall survival (OS) as compared to
the 362 samples without profile activity (HR = 3.61; 95%
CI = (1.24, 10.46); Figure 4B), with no significant differ-
ences in progression-free survival (PFS). As a special case,
we applied SISPA to define sample classes with decreased
CN and GE profiles for each gene in the KMS11-specific
cpt1 gene set. Samples with this profile for the genes, TP53,
TMEM102, MACROD2, FLRT3 and JAG1, had signifi-
cantly shorter OS compared to samples without this profile
(P < 0.05). The other genes could not be tested due to too
few samples with profile activity. Crucially, the HR for the
combined gene set was largest in magnitude, suggesting that
the observed survival effect was not driven entirely by one
gene with this profile, but rather the combined genes had
a cumulative effect. This is relevant since deletions of 17p
containing TP53 are an indicator of poor prognosis in MM.
Additionally, there was no significant association between
samples with and without profile activity and the presence
of a t(4;14) translocation based on cytogenetic data.
Lack of DNA methylation data in coMMpass precluded
direct interrogation of the three-feature profile gene set (Fig-
ure 3). However, with the exception of two genes, CN and
GE were prominent features driving this profile (Figure 3B).
Therefore, we applied SISPA based on the three-feature
gene set (Figure 3) to the available, prominent two features
(CN down, GE down) mostly associated with this gene set.
SISPA identified 25 patients with profile activity (Figure
4A), which compared to the 352 without profile activity, had
significantly (P = 0.027) shorter PFS (HR = 2.38; 95% CI =
1.07, 5.28; Figure 4B, bottom), and borderline significantly
(P = 0.057) shorter OS (HR = 2.69, 95% CI = 0.93, 7.82).
Driver mutations. The prognostic relevance of coding mu-
tations in MM is not well understood. The major reason
is that with the exception of those in KRAS, NRAS and
BRAF, most are relatively infrequent. Thus, popular mod-
els such as MutSig cannot inform on driver status. However,
an infrequently mutated gene with a functional association
to a known cancer gene or pathway may have a driving ef-
fect, regardless of mutation frequency. We applied a recent
software tool, HyperModules, to find frequently mutated
gene modules with clinical associations (9).
Using data from the coMMpass trial, we identified 58
patients with the following extreme prognostic classes:
(i) death or relapse within three months of treatment
(unfavorable-worse; n = 13); (ii) death or relapse at greater
than three months of treatment with at least one year of
follow-up (unfavorable-bad; n = 22); and (iii) alive and no
relapse with at least 2 years of follow-up (favorable; n =
23). We used GISPA to pre-filter the mutation list passed
to HyperModules based on the following hypothesis: an al-
lelic GE skewed toward the mutant implies either loss of
the wild type allele through deletion or epigenetic silenc-
ing, or amplification/hypomethylation of the mutant allele.
We reasoned that the ability to identify such scenarios could
increase the likelihood of identifying mutations with driver
status. We applied two-feature GISPA to identify somatic
mutations with increased GE using 58 samples. A straight-
forward application of GISPA, in which an average of each
data feature is used to define the profile statistic, was not
possible as most mutations were found in only one sample,
and thus the mean of a mutation type is at or near zero.
Instead, we formed 6578 trios using one patient from each
of the three prognostic classes, and combined all sample-
specific, expressed somatic mutations above cpt1 into a uni-
fied mutation list.
We applied HyperModules to our GISPA gene list using
as input a network derived from a random data split of the
58 patients into: (i) n = 29 patients (n = 19 unfavorable; n
= 10 favorable prognosis) using 529 GISPA-defined, cpt1
expressed somatic gene mutations and their identified close
connectors from the Reactome database (8); and (ii) 571
GISPA-defined, cpt1 expressed somatic gene mutations ob-
tained from the other n = 29 patients (n = 16 unfavorable;
n = 13 favorable prognosis) and their prognosis as either
‘favorable’ or ‘unfavorable’. We identified a 16 gene module
(P-value = 0.10) that included 9 genes, TP53 and TRAF3
among them, with expressed somatic mutations enriched in
10 newly diagnosed MM patients with unfavorable progno-
sis (Supplementary Figure S7). TP53, a well-known tumor
suppressor gene, is also mutated in MM, although only in
3% of cases (24). Activation of the non-canonical NF-kB
pathway by TRAF3 inactivation has been associated with
dexamethasone resistance and proteasome inhibitor sensi-
tivity (25). Using this approach, we identified TRAF3 ex-
pressed mutations with no corresponding NFKB1 mutation
as one of the module connections associated with unfavor-
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Figure 4. SISPA identifies patient samples clinical relevance of GISPA-defined gene sets. (A) Waterfall plot of SISPA scores based on pre-treatment copy
number (CN) and gene expression (GE) data on 377 newly diagnosed MM patient samples from the coMMpass trial using GISPA-defined KMS11
selected, change point 1 gene set results that satisfy the profile of (i) decreased CN with decreased GE (top; Figure 2) or (ii) decreased GE with increased
CpG methylation and decreased CN (bottom; Figure 3) to define samples with (in orange) and without (in grey) decreased CN and decreased GE profile
activity at pre-treatment. The KMS11 selected, GISPA-defined, three feature (GE, CN, methylation) gene set from Figure 3 was applied to the two features
(GE, CN) in the clinical data set from the coMMpass trial, since in the absence of available methylation data, with the exception of two genes, GE and CN
were prominent features. (B) Kaplan-Meier overall survival (top) and time to progression (bottom) plots for the SISPA defined sample classes. A log rank
test was used to compare survival curves and obtain corresponding P-values. The 15 samples with the profile activity (in orange) of decreased GE and
decreased CN based on the KMS11 selected gene set corresponding to this same profile (top) have significantly shorter survival as compared to the 362
samples without this profile activity (in grey). The 25 samples (in orange) with profile activity of decreased GE and decreased CN based on the KMS11
selected gene set corresponding to the profile of decreased GE with increased CpG methylation and decreased CN (bottom) have significantly shorter time
to progression as compared to the 352 samples without this profile activity (in grey).
able prognosis, revealing a potentially new connection be-
tween these genes.
We also identified a significant (P = 0.05) 11 gene mod-
ule that included 7 genes, BRAF among them, with ex-
pressed somatic mutations enriched in 8 newly diagnosed
MM patients with favorable prognosis (Supplementary Fig-
ure S8). In recent years, BRAF-V600E has been shown as
a promising ‘actionable’ mutation that can be targeted for
treatment (26). We found the BRAF-G466E mutation as
potentially associated with favorable prognosis. This mu-
tation has been previously reported as a low-frequency,
cancer-associated variant classified as an impaired activ-
ity mutant (less than wild-type BRAF activity) that moder-
ately increases ERK activation (27). Notably, neither prog-
nosis module was identified among the 13 significant (P <
= 0.05) modules when applying HyperModules to the full,
GISPA-unfiltered, mutation data from these patients, indi-
cating that the additional information on GE changes from
using GISPA had an effect that resulted in a very focused
set of modules. The separation of patient prognosis by mu-
tation profiles suggests an underlying common mechanism
worthy of separate investigation. The mutation network en-
riched in the favorable prognosis class in particular is a re-
search area that is aligned with the timely NCI exceptional
responder’s initiative.
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DISCUSSION
Although a comparison of our GISPA results based on dif-
ferent analytic approaches applied to the same data would
be ideal, such comparisons are not straightforward within
our context for many reasons, including the single sam-
ple sizes for each class, the several diverse genome-wide
data types simultaneously examined, and the supervised set-
ting. The nature of our experiment is such that three sin-
gle sample cell lines are to be compared among diverse,
genomewide data types in order to characterize each cell
line based on a priori specified, relative changes. Most, if
not all of the existing ‘integrated’ analysis tools are unable
to accommodate single sample analysis, a comparison of
more than two classes, and a priori specified change, and
more than two data types, for a direct comparison. By in-
troducing other tools that are appropriate for some but not
all experimental design aspects would produce ‘ad hoc’ re-
sults, and require a further understanding of differences in
how the design aspects were handled, in addition to differ-
ences in results. The one approach that does offer a more
direct comparison with GISPA and is frequently used and
straightforward to understand is the integration by intersec-
tion. We compared our three-feature GISPA results to those
based on an intersecting approach using commonly applied
thresholds and fold-change. A comparison based on three
features was done to highlight one of the novelties of the
GISPA method in being able to accommodate several di-
verse, genomewide data types. Despite conducting the inte-
gration by intersection analysis based on a specific, hypoth-
esized change, by implementing one-sided tests for greater
statistical power, no reported genes were selected as in com-
mon among the intersecting results and thus, no genes were
selected whose change in three features was characteris-
tic of the KMS11 selected cell line; the cell line we high-
lighted throughout the paper. By comparison, our GISPA
approached identified seven such genes. While we have not
performed an exhaustive confirmation of all seven genes se-
lected based on our GISPA approach, the results have been
supported in part by its ability to identify known genomic
changes in the cell lines and by experimental validation of
a novel, KMS11-cell line selected gene, EPS15, in terms of
decreased methylation, increased expression and decreased
copy number relative to multiple myeloma cell lines, MM1s
and RPMI-8226.
Our GISPA methodology identified both known and
novel gene abnormalities specific to each MM cell line
within the context of a priori specified molecular profiles.
Furthermore, our analyses show that these gene sets have
clinical and biological relevance. While this proof of prin-
ciple was based on a three sample, three class comparison,
the methods can be generalized to n comparisons among n
classes with each class containing multiple samples. We fur-
ther show how GISPA can be used on a larger patient data
set with three prognostic classes, each containing several
samples per class, to define mutation profiles enriched in
each class. Methods to filter mutations as drivers is of con-
siderable interest and remains a challenge, mainly because
of lack of approaches to address the low frequency of poten-
tial key mutations. Our novel application of GISPA results
to HyperModules offered new prognostic associations for
known mutations. There are many potential applications of
GISPA, including deriving high, standard and low risk can-
cer profiles or mutation profiles over a time-course experi-
ment. SISPA could subsequently be used to classify future
samples or to identify the best cell line models for each cat-
egory. Using SISPA to define sample classes with and with-
out profile activity, a Gene Set Enrichment Analysis (28)
may then be performed to further identify differential path-
ways.
While we provided examples of several profiles that may
be tested as characterizing each cell line using GISPA, there
are limitations to the data types that precludes an exhaus-
tive search. For example, the GISPA-defined, cpt1 gene set
supporting the three feature profile of decreased GE with
increased CpG methylation and decreased CN as charac-
teristic of each cell line (Figure 3), may in fact be driven
by miRNA-mediated down-regulation. Based on a query
of individual genes against several miRNA databases (see
Appendix 3: Methods), we examined whether any miRNA
commonly targets all or most genes in this set and iden-
tified hsa-miR-656 as predicted to target 6 of the seven
genes, followed by hsa-miR-587, targeting five of the seven
genes (Supplementary Table S5); both predictions included
EPS15.
The GISPA approach may be optimized and modified at
any step, without loss of generality of the overall method.
For example, one may incorporate weights into the WFPS
or BFPS profile to penalize poorly supported coding vari-
ants or to place a greater emphasis on a particular feature.
Additionally, one may estimate the significance of ranked
GISPA-defined gene sets (see Appendix, ‘Gene Set Signif-
icance’). For example, the three feature profile identified 7
(out of 10) significant GISPA-defined KMS11 selected gene
sets with decreased GE and CN and increased methylation.
As newer technology is generated, tools such as GISPA
will help to integrate them with existing diverse data types
in a way that tests specified profiles as drivers of a phenotype
to infer new clinical and biological associations that may be
used for their better understanding.
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